AnaptysBio (NASDAQ:ANAB) Downgraded by BTIG Research to Neutral

AnaptysBio (NASDAQ:ANAB) was downgraded by equities research analysts at BTIG Research from a “buy” rating to a “neutral” rating in a report released on Monday, MarketBeat.com reports.

Several other equities analysts also recently issued reports on the stock. Truist Financial upped their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Guggenheim upped their target price on AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, October 21st. HC Wainwright cut their price target on AnaptysBio from $55.00 to $52.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. UBS Group increased their price objective on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Finally, Wedbush restated an “outperform” rating and set a $42.00 target price on shares of AnaptysBio in a research report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.64.

AnaptysBio Stock Down 0.6 %

ANAB stock opened at $24.96 on Monday. The business has a 50 day moving average price of $28.13 and a 200 day moving average price of $29.74. The stock has a market cap of $759.53 million, a price-to-earnings ratio of -4.11 and a beta of -0.24. AnaptysBio has a fifty-two week low of $13.96 and a fifty-two week high of $41.31.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The business had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. As a group, sell-side analysts anticipate that AnaptysBio will post -6.02 EPS for the current year.

Insider Buying and Selling

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the sale, the insider now owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. The trade was a 8.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $39.91, for a total value of $487,700.20. Following the transaction, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at approximately $189,333.04. This trade represents a 72.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,440 shares of company stock valued at $892,936 over the last three months. 33.70% of the stock is currently owned by company insiders.

Institutional Trading of AnaptysBio

Institutional investors have recently modified their holdings of the business. Ensign Peak Advisors Inc lifted its holdings in AnaptysBio by 74.4% in the second quarter. Ensign Peak Advisors Inc now owns 75,755 shares of the biotechnology company’s stock valued at $1,898,000 after acquiring an additional 32,313 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of AnaptysBio by 55.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after purchasing an additional 168,813 shares in the last quarter. Victory Capital Management Inc. lifted its stake in shares of AnaptysBio by 677.9% in the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after purchasing an additional 206,750 shares during the period. Alpha DNA Investment Management LLC purchased a new stake in AnaptysBio during the second quarter worth about $399,000. Finally, nVerses Capital LLC grew its position in AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after buying an additional 1,400 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.